#novo-nordisk-layoffs

#novo-nordisk-layoffs

Thousands of Oracle employees in India have received layoff notices as part of what the company described as a 'reduction in force and other terminations.' Indian outlets said between 10,000 and 12,000 employees in the country could be affected.

The layoffs are part of a transformation plan approved by Takeda's board on March 25, expected to generate more than 200 billion Japanese yen in annualized savings by fiscal 2028, or about $1.25 billion.

About 40% of Chinese employees stay in one job for less than two years, according to a Hay Group study. In India, annual turnover of 50% or more is not unusual. That's clearly a problem, not only because constantly recruiting and training people over and over again is expensive, but because it's disruptive. Continuity, let alone growth, can be tough to maintain when half your team is made up of brand-new faces every few months.

The majority of the proposed cuts are expected to fall within the retailer's technology and data division, with Sainsbury's indicating that roles may be selected based on efficiency needs, strategic priorities, and fairness criteria. However, specific criteria and processes have not yet been disclosed, and the company plans to provide further details during consultations.

Walgreens has announced that it will cut at least 628 jobs across two states, according to communications it sent to the states in question earlier this month. A Walgreens spokesperson confirmed the layoffs with Fast Company when reached for comment. News of the layoffs was first reported by Bloomberg. The job cuts include 469 positions in the company's home state of Illinois and 159 jobs in Texas, where the company is shuttering a distribution center.

The Wegovy pill-which has been in clinical trials for over two years and was approved by the FDA on December 22-is the first and only oral GLP-1 for weight loss in adults available in the U.S. According to a press release from Novo Nordisk, the pill hit the market on January 5 at more than 70,000 U.S. pharmacies and several popular telehealth providers. Per a KFF health tracking poll released in November, one in eight Americans were already taking a GLP-1 for weight-loss.

Medtronic ( NYSE: MDT) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026. Cardiac Ablation Drives Outperformance The Cardiovascular Portfolio led the quarter with 13.8% reported growth, powered by an exceptional 80% surge in Cardiac Ablation Solutions. U.S. cardiac ablation revenue exploded 137%, driven by the company's pulsed field ablation (PFA) portfolio. Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes posted 8.3% organic growth to $796 million.

From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher. The past couple of years have been a transformative time for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines and GLP-1 drugs, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. Meanwhile, it has struggled to meet overwhelming demand and faces intense competition in the weight-loss space.

For pharmaceutical giant Bristol Myers Squibb (BMS), the moment came following its $74 billion acquisition in 2019 of Celgene Corp., when BMS had to fund a major post-merger integration while preparing for the expiration of valuable pharmaceutical patents. Determined to make the most of the opportunity presented by the merger, one of the largest ever in the pharmaceutical industry, BMS leaders have since embarked on an enterprise-wide initiative to modernize departments and improve the use of technology and innovation.

We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.

At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure. It now powers our R&D decisions, our supply chain and manufacturing processes, and most importantly how we discover and develop medicines. All businesses that have implemented AI in an impactful way face challenges, such as skills gaps and uncertainty, but you move beyond that by embedding AI deeply into teams and systems. This enables AI to become a key, reliable source of sustained productivity and innovation.

Bristol Myers' Growth Portfolio surged 16% to $7.4 billion in Q4, demonstrating the company's successful product diversification strategy. Key contributors included Opdivo at $2.69 billion (+9%), Eliquis at $3.45 billion (+8%), and standout performers Breyanzi at $392 million (+49%) and Camzyos at $353 million (+59%). However, the Legacy Portfolio declined 15% to $5.1 billion as generic competition intensified. Revlimid plummeted 55%, while Sprycel dropped 60%, reflecting the patent cliff challenges facing the company.